SCYNEXIS (SCYX) Registration filing summary

Company overview and business model

• Clinical-stage biotech focused on severe rare diseases; pipeline strategy emphasizes differentiated candidates with novel mechanisms and potential clinical and commercial value.

• Lead candidate SCY-770 is a selective direct AMPK activator for ADPKD; SCY-247 is in clinical development for invasive candidiasis and fungal-disease prevention.

• Antifungal platform includes BREXAFEMME (ibrexafungerp), licensed to GSK in May 2023; commercialization also relies on Hansoh and R-Pharm in specified regions.

Financial performance and metrics

• Limited profitability history and limited product-sales revenue to date; the only approved commercial product is licensed to GSK, and substantial additional capital is expected to be needed.

• Potential GSK relaunch-related proceeds include up to $146.0 million in annual net-sales milestones plus royalties; timing and achievement remain uncertain.

Use of proceeds and capital allocation

• Net proceeds are intended for working capital and general corporate purposes; management has broad discretion, with allocation dependent on R&D, clinical, partnering and market developments.

• Pending use, proceeds are expected to be invested temporarily in short-term, interest-bearing instruments.